Compare S&P Global Inc (SPGI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Zoetis Inc — how do they compare? S&P Global Inc trades at $407.82 (market cap $118.72B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: S&P Global Inc is far larger — about 3.9× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and Zoetis Inc for 70 Days on average.
| SPGI | ZTS | |
|---|---|---|
Market Cap | $118.72B | $30.20B |
Volume | 1,647,917 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $517.92 | $147.53 |
52-Week Low | $370.42 | $69.09 |
Typical Hold Time | 123 Days | 70 Days |
Enterprise Value | $130.21B | $37.76B |
Dividend Yield | 0.96% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $402.73, up 1.91% with strong analyst support (85.7% buy ratings) and a $509.50 consensus price target. The stock shows solid fundamentals with 30.54% net margins and consistent revenue growth from $14.2B to $15.3B. Recent technical indicators show bearish momentum despite beating earnings expectations in two of the last three quarters. The company continues expanding through strategic acquisitions like OpenZeppelin and new product launches in digital asset risk assessment.
SPGI presents a compelling growth story with expanding margins and strategic positioning in financial data services. Key risks include market sensitivity to economic cycles and integration challenges from recent acquisitions. With strong cash flow generation and a dominant market position, the stock offers upside potential despite near-term technical weakness.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
